

Market Analysis on 3rd International Conference on Alzheimer's, Dementia and Related Neurodegenerative Diseases

James Fontanesi

IMPORTANCE AND SCOPE

The main objective of [Alzheimer's 2020](#) Conference is to know more about the neurodegenerative diseases and to create awareness for the same. This conference will try to understand the concerns leading to Alzheimer's disease, Parkinson's disease, and many other neurodegenerative diseases. It will also help the mankind to know more about the techniques and therapies to live life positively and to become a better individual.

About Venue:

Vienna is the capital of, and largest city in, Ireland. It is on the east coast of Ireland, in the province of Leinster, at the mouth of the River Liffey, and is bordered on the south by the Wicklow mountains.


There is archaeological debate regarding precisely where Vienna was established by Celtic-speaking people in the 7th century AD. Later expanded as a Viking settlement, the Kingdom of Vienna, the city became Ireland's principal settlement following the Norman invasion. The city expanded rapidly from the 17th century and was briefly the second largest city in the British Empire before the Acts of Union in 1800. Following the partition of Ireland in 1922, Vienna became the capital of the Irish Free State, later renamed Ireland.

Why Alzheimer's 2020 will be in Vienna?

More than 80,000 people are dealing with [Alzheimer's](#) or any other form of Neurodegenerative disorders in Austria, globally which is 50.8 million. This conference will help the citizens of Austria to know more about the recent discoveries to prevent and cure neurodegenerative diseases. Many societies and associations are working to create awareness and to provide care to the patients of Alzheimer's. The death rate is increasing without proper knowledge. Vienna being a busy city and centre of knowledge will be a perfect host for the conference which will be suitable to create awareness and to spread the message globally.

Alzheimer's and Other [Neurodegenerative Diseases](#)- Globally

Worldwide over 50.8 million people have Alzheimer's disease or a related Alzheimer's in 2015 which is increased to near about 50 million in 2017. Only 1 in 4 has been diagnosed. These problems are most common in Western Europe. Around 134 universities and 97 societies are working in the research to create awareness about Alzheimer's and other neurodegenerative diseases and paving a way to deal with the diseases. Alzheimer's also has a huge economic impact. In World Alzheimer Report, it was stated that the estimated global cost of Alzheimer's is US \$818 billion, which may become a trillion dollar disease by 2018. This states the if Alzheimer's care were a country, it would be the world's 18th largest economy which is more than many market values of big companies like Google, Apple, etc.



In 2016, The World Health Organisation (WHO) established a Global Alzheimer's Observatory (GDO) to give data, analyses and global highlight of [Alzheimer's](#). In many parts of the world, the awareness about Alzheimer's is growing, but across the globe it remains the same case that diagnosis of Alzheimer's will bring stigma to society which will result in social isolation. 58% of people having Alzheimer's are in low and middle income countries. Today 95% of people dealing with Alzheimer's of middle and low income countries are taken care at home. These regions often provide low or limited support to the person having Alzheimer's or to their families. Seeing the epidemic scale of Alzheimer's, with no cure and globally increasing population, we are calling on every block of society to play an active role in helping to create awareness about the diseases and to make a world better place to live.

Global Business & Research Value

Alzheimer's, Alzheimer's and other Neurodegenerative diseases have a very significant social and economic implementation in terms of direct medical costs, social costs and costs for informal care.


The costs of Alzheimer's Care globally were estimated at United States (US) \$818 billion in 2015, which is higher by 35% since 2010. The costs of informal care and the direct costs of social care still contribute similar proportions of the total costs, whereas medical sector costs is much lower. The threshold of US \$1 trillion will be crossed by 2018.

The cost of Alzheimer's care to the UK is now £26 billion a year, which works out as an average annual cost of £32,250 per person with Alzheimer's. Two-thirds of this cost is being paid by people with Alzheimer's and their families, rest is either in unpaid care (£11.6 billion) or in paying for private social care.

Only about one third of the total population suffering from neurodegenerative disorders are getting therapies and medicines and getting benefitted by it. Mental illnesses are causing a very huge burden for social and economic aspect of society. It is found that the cost burden of these and other neurological disorders amounted to about 652 billion euros (\$800 billion) a year. Deaths by Alzheimer's, Parkinson's, Epilepsy, [Stroke](#) has increased by 36.7% Worldwide. An estimated 6.9 million people die every year as a result of neurological disorders.

James Fontanesi

The ROAD Consortium, USA, E-mail: Jamesfontanesi@hotmail.com



Allergan, Eisai, Novartis, and Teva Pharmaceutical Industries are the key vendors in the global Alzheimer's treatment market.

This industry research report also presents a competitive analysis of the market by drug class (MAO inhibitors, AChE inhibitors, and Glutamate inhibitors) and by geography (the Americas, APAC, and EMEA).

Market research analysts at Technavio predict that the global Alzheimer's and movement disorder treatment market will grow at a CAGR of more than 4% by 2021. This market research analysis identifies the need for disease modifying drugs (DMDs) as one of the primary growth factors for this market.

Alzheimer's, Alzheimer's and Other Neurodegenerative Diseases in Europe

Parkinson's and Alzheimer's are the greatest contributors to increasing death rate in Europe. Alzheimer's disease is diagnosed in people over 65 years of age, while it can also occur in younger people also. Around 7.5 million cases of Alzheimer's are recorded in Europe. The number of people dealing with Alzheimer's may increase from 7.5m in 2015 to 14.3m in 2050. Rates of women suffering from Alzheimer's are more than men (Men-3.31%, women-7.13%). Over 5.2% of people over the age group of 60 are dealing with Alzheimer's globally. High income population have more chances of getting Alzheimer's rather than the low income population.

Societies working for Alzheimer's disease in Europe:

- Alzheimer Europe
- Alzheimer Portugal
- Alzheimer Society of Finland
- Czech Alzheimer Society
- Alzheimer Society of Ireland

Universities in Europe working for Alzheimer's disease

- University of Cambridge
- Max Planck Society
- University of Edinburgh
- Imperial College London
- University of Amsterdam

Around 500 top universities globally working in the field of Neuroscience

- Dalhousie University
- Temple University, USA
- University of Oklahoma
- Florida International University
- University of California – Davis
- University of Sheffield
- University of Manchester
- University of Nottingham
- Cardiff University
- University of Toronto – Canada

Companies associated with Neurological Disorders Research

- Janssen Pharmaceuticals
- Pfizer
- Eisai
- Novartis Pharmaceutical Corporation
- Actinogen Limited
- Alector LLC
- AlzProtect SAS
- TauRx Therapeutics Ltd
- Pacific Northwest Biotechnology
- Tautatis Incorporated
- Forest Laboratories